Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer - Related Studies

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

This study is ongoing, but not recruiting participants.

Study NCT00075868. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Anal Cancer
		Cancer-Related Problem/Condition
		Colorectal Cancer

2	Additional conditions recognized in this trial
		Anus Neoplasms
		Colorectal Neoplasms
		Rectal Neoplasms

3	More general conditions related to this trial
		Anus Diseases
		Colonic Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Intestinal Diseases
		Intestinal Neoplasms
		Neoplasms
		Neoplasms by Site
		Rectal Diseases

4	Interventions listed in this trial
		octreotide acetate

5	Additional drug interventions recognized in this trial
		Octreotide

6	More general drug interventions related to this trial
		Antineoplastic Agents
		Antineoplastic Agents, Hormonal
		Gastrointestinal Agents
		Pharmacologic Actions
		Therapeutic Uses

7	Sponsors listed in this trial
		Radiation Therapy Oncology Group
		National Cancer Institute (NCI)